Latest Market News

Botala Energy Ltd has denied holding undisclosed information following a sharp share price rise, linking the spike to a recent Serowe CBM Project announcement and confirming compliance with ASX disclosure rules.

Breakthrough Minerals (ASX:BTM) has secured A$5.15 million through a placement to fund a substantial expansion of its drilling program at the North Queensland Copper-Gold Project, aiming to grow its resource base beyond 200,000 tonnes of contained copper equivalent.

The Hydration Pharmaceuticals Company Limited (ASX: HPC) has had its trading suspension lifted as of 4 May 2026, following the lodgement of its delayed Annual Report revealing a $2.86 million net loss.

Condor Energy secures A$2.25 million in a placement to advance licence conversion, gas commercialisation, and exploration drilling readiness in its offshore Peru portfolio.

American West Metals (ASX: AW1) has raised A$10 million through an oversubscribed institutional placement to fast-track exploration at its West Desert and Storm Copper projects, focusing on high-demand critical metals.

Athena Resources is raising $3.5 million through a discounted share placement backed by major investors to fast-track drilling and feasibility at its Narryer magnetite project.

Litchfield Minerals denies undisclosed material information behind recent share price jump, pointing to public engagement, media activity, and early-stage exploration sample processing as key influences.

SSH Group Ltd is set to acquire Elphinstone Mechanical Services, boosting its revenue scale and geographic reach into Queensland and New South Wales with an immediately accretive deal.

Imricor Medical Systems has secured A$60 million through a placement to fund its US commercial rollout, regulatory approvals, and clinical programs, boosting its cash reserves to nearly A$103 million.

Vanadium Resources raises about A$1 million through a placement to fund studies and site agreements for its Steelpoortdrift Vanadium Project and next-gen V-Iron Plant, aiming to supply Western critical mineral markets.

Entropy Neurodynamics has unveiled a striking 75% response rate in a small Phase 2a trial of its oral psilocybin therapy for treatment-resistant irritable bowel syndrome, far surpassing existing treatments and validating its gut-brain axis approach.

Cynata Therapeutics has secured A$1.5 million through an institutional placement priced at a 22.5% discount, aiming to extend its cash runway ahead of pivotal Phase 3 and Phase 2 trial results expected in May and June 2026.